Procter & Gamble Health · NSE: PGHL · BSE: 500126
Q4 FY21 results · Jan–Mar 2021
Procter & Gamble Health reported revenue from operations of ₹219.15 crore (down 3.9% from Q4 FY20) and net profit of ₹15.77 crore (down 66.1% from Q4 FY20) for Q4 FY21 (Jan–Mar 2021), on a standalone basis.
| Item | Q4 FY21 | Q4 FY20 | YoY | Q3 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 219.15 | 228.11 | −3.9% | 240.22 | −8.8% |
| Other income | 3.24 | 10.26 | −68.4% | 5.72 | −43.4% |
| Total income | 222.39 | 238.37 | −6.7% | 245.94 | −9.6% |
| Profit before tax | 26.10 | 64.76 | −59.7% | 86.43 | −69.8% |
| Net profit for the period | 15.77 | 46.46 | −66.1% | 67.88 | −76.8% |
| EPS, basic (₹) | 9.50 | 27.99 | −66.1% | 40.90 | −76.8% |
| Net margin (%) | 7.2 | 20.4 | 28.3 |
Standalone
- Filed with BSE
- 06 May 2021, 20:24 IST
- Board meeting
- 06 May 2021
- Period
- 01 Jan 2021 to 31 Mar 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE